Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guido Rovera

Showing results (31-40 of 43) with videos related to

Pageof 5
Sort By:
Medicina (Kaunas, Lithuania)|August 26, 2023
Long-Term Retention Rate of Tofacitinib in Rheumatoid Arthritis: An Italian Multicenter Retrospective Cohort StudyMarino Paroli, Andrea Becciolini, Elena Bravi, et al.
Medicina (Kaunas, Lithuania)|January 8, 2025
Effectiveness and Predictors of Long-Term Treatment Response to Tofacitinib in Rheumatoid Arthritis Cohort: General Analysis and Focus on High-Cardiovascular-Risk Subgroup-A Multicenter StudyMarta Priora, Andrea Becciolini, Eleonora Celletti, et al.
Journal of Clinical Medicine|July 13, 2024
Influence of Safety Warnings on the Prescribing Attitude of JAK Inhibitors for Rheumatoid Arthritis in ItalyMarino Paroli, Andrea Becciolini, Alberto Lo Gullo, et al.
Minerva Medica|October 8, 2024
Multicenter observational study on the efficacy of selective Janus Kinase-1 inhibitor upatacitinib in rheumatoid arthritisAlberto Lo Gullo, Simone Parisi, Andrea Becciolini, et al.
Therapeutic Advances in Musculoskeletal Disease|May 11, 2026
Drug retention of TNF versus IL-23 inhibitors in psoriatic arthritis: a multicenter real-life cohort studySimone Parisi, Andrea Becciolini, Bernardo D'Onofrio, et al.
Frontiers in Pharmacology|March 6, 2025
Efficacy and safety profile of biotechnological agents and Janus kinase inhibitors in VEXAS syndrome: data from the international AIDA Network VEXAS registryAntonio Vitale, Valeria Caggiano, Flavia Leone, et al.
Rheumatology and Therapy|December 4, 2025
Filgotinib Effectiveness in Rheumatoid Arthritis: Observational Analysis of a Large Multicenter CohortEleonora Celletti, Myriam Di Penta, Alarico Ariani, et al.
Journal of Psoriasis and Psoriatic Arthritis|June 12, 2026
Ixekizumab Treatment Persistence in Psoriatic Arthritis: Response to Joaquin et alCamilla Mazzanti, Marino Paroli, Gianluca Santoboni, et al.
Journal of Psoriasis and Psoriatic Arthritis|May 16, 2025
Ixekizumab Retention Rate and Predictors of Treatment Persistence in Psoriatic Arthritis: Results of an Italian Multicenter StudyCamilla Mazzanti, Marino Paroli, Gianluca Santoboni, et al.
Mediterranean Journal of Rheumatology|June 29, 2026
Real-World Effectiveness of Baricitinib in Rheumatoid Arthritis: Significant Reduction of Disease Activity Independent of Age in a Multicentre Retrospective Cohort StudyDaniele Lini, Matteo Colina, Romina Andracco, et al.
Pageof 5

Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
Medicina (Kaunas, Lithuania)|August 26, 2023
Long-Term Retention Rate of Tofacitinib in Rheumatoid Arthritis: An Italian Multicenter Retrospective Cohort StudyMarino Paroli, Andrea Becciolini, Elena Bravi, et al.
Medicina (Kaunas, Lithuania)|January 8, 2025
Effectiveness and Predictors of Long-Term Treatment Response to Tofacitinib in Rheumatoid Arthritis Cohort: General Analysis and Focus on High-Cardiovascular-Risk Subgroup-A Multicenter StudyMarta Priora, Andrea Becciolini, Eleonora Celletti, et al.
Journal of Clinical Medicine|July 13, 2024
Influence of Safety Warnings on the Prescribing Attitude of JAK Inhibitors for Rheumatoid Arthritis in ItalyMarino Paroli, Andrea Becciolini, Alberto Lo Gullo, et al.
Minerva Medica|October 8, 2024
Multicenter observational study on the efficacy of selective Janus Kinase-1 inhibitor upatacitinib in rheumatoid arthritisAlberto Lo Gullo, Simone Parisi, Andrea Becciolini, et al.
Therapeutic Advances in Musculoskeletal Disease|May 11, 2026
Drug retention of TNF versus IL-23 inhibitors in psoriatic arthritis: a multicenter real-life cohort studySimone Parisi, Andrea Becciolini, Bernardo D'Onofrio, et al.
Frontiers in Pharmacology|March 6, 2025
Efficacy and safety profile of biotechnological agents and Janus kinase inhibitors in VEXAS syndrome: data from the international AIDA Network VEXAS registryAntonio Vitale, Valeria Caggiano, Flavia Leone, et al.
Rheumatology and Therapy|December 4, 2025
Filgotinib Effectiveness in Rheumatoid Arthritis: Observational Analysis of a Large Multicenter CohortEleonora Celletti, Myriam Di Penta, Alarico Ariani, et al.
Journal of Psoriasis and Psoriatic Arthritis|June 12, 2026
Ixekizumab Treatment Persistence in Psoriatic Arthritis: Response to Joaquin et alCamilla Mazzanti, Marino Paroli, Gianluca Santoboni, et al.
Journal of Psoriasis and Psoriatic Arthritis|May 16, 2025
Ixekizumab Retention Rate and Predictors of Treatment Persistence in Psoriatic Arthritis: Results of an Italian Multicenter StudyCamilla Mazzanti, Marino Paroli, Gianluca Santoboni, et al.
Mediterranean Journal of Rheumatology|June 29, 2026
Real-World Effectiveness of Baricitinib in Rheumatoid Arthritis: Significant Reduction of Disease Activity Independent of Age in a Multicentre Retrospective Cohort StudyDaniele Lini, Matteo Colina, Romina Andracco, et al.
Pageof 5